{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:42:50Z","timestamp":1793295770861,"version":"4.5.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100011790","name":"Xiangya Hospital Central South University","doi-asserted-by":"publisher","award":["2023JJ60520"],"award-info":[{"award-number":["2023JJ60520"]}],"id":[{"id":"10.13039\/501100011790","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Sixth Affiliated Hospital, School of Medicine, South China University of Technology","award":["FSZD145035"],"award-info":[{"award-number":["FSZD145035"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jad.2025.119670","type":"journal-article","created":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T10:59:58Z","timestamp":1749898798000},"page":"119670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Depression and suicide\/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database"],"prefix":"10.1016","volume":"389","author":[{"given":"Min","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.jad.2025.119670_bb0005","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/brainsci13111503","article-title":"GLP-1 receptor agonists and related mental health issues; insights from a range of social media platforms using a mixed-methods approach","volume":"13","author":"Arillotta","year":"2023","journal-title":"Brain Sci."},{"issue":"4","key":"10.1016\/j.jad.2025.119670_bb0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.jad.2025.119670_bb0015","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1007\/s40618-024-02441-z","article-title":"The real-world safety profile of tirzepatide: pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database","volume":"47","author":"Caruso","year":"2024","journal-title":"J. Endocrinol. Investig."},{"issue":"1","key":"10.1016\/j.jad.2025.119670_bb0020","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2023.2474","article-title":"Postmarket safety profile of suicide\/self-injury for GLP-1 receptor agonist: a real-world pharmacovigilance analysis","volume":"66","author":"Chen","year":"2023","journal-title":"Eur. Psychiatry"},{"issue":"7","key":"10.1016\/j.jad.2025.119670_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/ph16070994","article-title":"Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration\u2019s FDA adverse events reporting system (FAERS) pharmacovigilance dataset","volume":"16","author":"Chiappini","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"10.1016\/j.jad.2025.119670_bb0030","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.3390\/nu15051173","article-title":"The Association of Emotional Eating with overweight\/obesity, depression, anxiety\/stress, and dietary patterns: a review of the current clinical evidence","volume":"15","author":"Dakanalis","year":"2023","journal-title":"Nutrients"},{"key":"10.1016\/j.jad.2025.119670_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.chiabu.2022.105865","article-title":"Mental health of unaccompanied refugee minors in Europe: a systematic review","volume":"133","author":"Daniel-Calveras","year":"2022","journal-title":"Child Abuse Negl."},{"issue":"1","key":"10.1016\/j.jad.2025.119670_bb0040","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41398-024-03115-3","article-title":"Trajectories and predictors of suicidal ideation in clinical characteristics and pharmacological treatments for major depressive disorder: a study based on a national multi-centered prospective cohort","volume":"14","author":"Ding","year":"2024","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.jad.2025.119670_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1442490","article-title":"Country-specific psychopharmacological risk of reporting suicidality comparing 38 antidepressants and lithium from the FDA adverse event reporting system, 2017-2023","volume":"15","author":"Eugene","year":"2024","journal-title":"Front. Psychiatry."},{"key":"10.1016\/j.jad.2025.119670_bb0050","author":"European Medicines Agency"},{"key":"10.1016\/j.jad.2025.119670_bb0055","author":"Federation WO"},{"issue":"6","key":"10.1016\/j.jad.2025.119670_bb0060","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"10.1016\/j.jad.2025.119670_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152461","article-title":"Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: an analysis of postmarketing spontaneous safety reports","volume":"67","author":"Goldman","year":"2024","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jad.2025.119670_bb0070","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.euroneuro.2024.02.003","article-title":"Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: insights from pharmacovigilance measures and unmasking analysis","volume":"82","author":"Guirguis","year":"2024","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2025.119670_bb0075","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jad.2022.12.053","article-title":"Attentional control deficits and suicidal ideation variability: an ecological momentary assessment study in major depression","volume":"323","author":"Herzog","year":"2023","journal-title":"J. Affect. Disord."},{"issue":"Suppl. 1","key":"10.1016\/j.jad.2025.119670_bb0080","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/jdi.12464","article-title":"Neural effects of gut- and brain-derived glucagon-like peptide-1 and its receptor agonist","author":"Katsurada","year":"2016","journal-title":"J. Diabetes Investig."},{"issue":"2","key":"10.1016\/j.jad.2025.119670_bb0085","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1097\/SLA.0000000000004232","article-title":"Risk factors for suicide after bariatric surgery in a population-based nationwide study in five nordic countries","volume":"275","author":"Kauppila","year":"2022","journal-title":"Ann. Surg."},{"issue":"12","key":"10.1016\/j.jad.2025.119670_bb0090","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jamapediatrics.2024.3812","article-title":"Risk of suicidal ideation or attempts in adolescents with obesity treated with GLP1 receptor agonists","volume":"178","author":"Kerem","year":"2024","journal-title":"JAMA Pediatr."},{"issue":"1","key":"10.1016\/j.jad.2025.119670_bb0095","doi-asserted-by":"crossref","first-page":"24433","DOI":"10.1038\/s41598-024-75965-2","article-title":"The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy","volume":"14","author":"Kornelius","year":"2024","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.jad.2025.119670_bb0100","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/0018578718795271","article-title":"The newly available FAERS public dashboard: implications for health care professionals","volume":"54","author":"Kumar","year":"2019","journal-title":"Hosp. Pharm."},{"issue":"1","key":"10.1016\/j.jad.2025.119670_bb0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/14740338.2023.2295397","article-title":"The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse event Reporting System (FAERS)","volume":"23","author":"McIntyre","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jad.2025.119670_bb0110","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.jad.2024.10.062","article-title":"Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: a replication study using reports to the World Health Organization pharmacovigilance database (VigiBase\u00ae)","volume":"369","author":"McIntyre","year":"2025","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.119670_bb0115","article-title":"Risk of suicide, hair loss, and aspiration with GLP1-receptor agonists and other diabetic agents: a real-world pharmacovigilance study","author":"Nakhla","year":"2024","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"10","key":"10.1016\/j.jad.2025.119670_bb0120","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1007\/s11695-024-07486-w","article-title":"Role of GLP1-RA in optimizing weight loss post-bariatric surgery: a systematic review and meta-analysis","volume":"34","author":"Pereira","year":"2024","journal-title":"Obes. Surg."},{"issue":"1","key":"10.1016\/j.jad.2025.119670_bb0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/med.22070","article-title":"Incretin-based therapies for the management of cardiometabolic disease in the clinic: past, present, and future","volume":"45","author":"Psaltis","year":"2025","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.jad.2025.119670_bb0130","doi-asserted-by":"crossref","DOI":"10.2174\/0115748863330434241015125302","article-title":"Role of dual GIP and GLP-1 receptor agonist, Tirzepatide in the management of weight loss; a systematic review","author":"Rangraze","year":"2024","journal-title":"Curr. Drug Saf."},{"key":"10.1016\/j.jad.2025.119670_bb0135","author":"Ritchie"},{"issue":"2","key":"10.1016\/j.jad.2025.119670_bb0140","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/ph17020147","article-title":"Glucagon-like peptide-1 receptor agonists and suicidal ideation: analysis of real-word data collected in the European Pharmacovigilance Database","volume":"17","author":"Ruggiero","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.jad.2025.119670_bb0145","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"issue":"1","key":"10.1016\/j.jad.2025.119670_bb0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1071\/HC21122","article-title":"Decision-making on listing new medicines for public funding in New Zealand: the case of \u2018new\u2019 type 2 diabetes medications","volume":"14","author":"Sarkisova","year":"2022","journal-title":"J. Prim. Health Care"},{"issue":"8","key":"10.1016\/j.jad.2025.119670_bb0155","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.23385","article-title":"Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality","volume":"7","author":"Schoretsanitis","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jad.2025.119670_bb0160","article-title":"Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system database","volume":"17","author":"Shirani","year":"2024","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.jad.2025.119670_bb0170","doi-asserted-by":"crossref","DOI":"10.1192\/j.eurpsy.2023.2419","article-title":"Viewpoint: assessing the value of mental health treatments in Europe","volume":"66","author":"Simon","year":"2023","journal-title":"Eur. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2025.119670_bb0175","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/YCO.0000000000000952","article-title":"GLP-1 receptor agonists and weight loss in schizophrenia - past, present, and future","volume":"37","author":"Trott","year":"2024","journal-title":"Curr. Opin. Psychiatry"},{"issue":"11","key":"10.1016\/j.jad.2025.119670_bb0180","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/jamainternmed.2024.4369","article-title":"GLP-1 receptor agonist use and risk of suicide death","volume":"184","author":"Ueda","year":"2024","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jad.2025.119670_bb0185","author":"US Food and Drug Administration"},{"issue":"1","key":"10.1016\/j.jad.2025.119670_bb0190","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3892\/etm.2023.12054","article-title":"Therapeutic management of atypical antipsychotic-related metabolic dysfunctions using GLP-1 receptor agonists: a systematic review","volume":"26","author":"Vasiliu","year":"2023","journal-title":"Exp. Ther. Med."},{"issue":"10294","key":"10.1016\/j.jad.2025.119670_bb0195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(21)00798-4","article-title":"Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18","volume":"398","author":"Wang","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jad.2025.119670_bb0200","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1177\/02698811211035391","article-title":"Efficacy and tolerability of pharmacological interventions on metabolic disturbance induced by atypical antipsychotics in adults: a systematic review and network meta-analysis","volume":"35","author":"Wang","year":"2021","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2025.119670_bb0205","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat. Med."},{"issue":"24","key":"10.1016\/j.jad.2025.119670_bb0210","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","article-title":"Once-weekly semaglutide in adolescents with obesity","volume":"387","author":"Weghuber","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jad.2025.119670_bb0215","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jad.2025.119670_bb0220","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jad.2025.119670_bb0225","doi-asserted-by":"crossref","DOI":"10.1186\/s40360-024-00789-9","article-title":"Stratified analysis of the association between anti-obesity medications and digestive adverse events: a real-world study based on the FDA adverse event reporting system database","volume":"25","author":"Yang","year":"2024","journal-title":"BMC Pharmacol. Toxicol."},{"issue":"8","key":"10.1016\/j.jad.2025.119670_bb0230","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1007\/s00406-021-01371-8","article-title":"Spontaneous transient states of fronto-temporal and default-mode networks altered by suicide attempt in major depressive disorder","volume":"272","author":"Zhang","year":"2022","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.jad.2025.119670_bb0235","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s13098-023-01198-4","article-title":"Efficacy and safety of tirzepatide, dual GLP-1\/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Zhou","year":"2023","journal-title":"Diabetol. Metab. Syndr."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725011127?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725011127?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:57:53Z","timestamp":1776920273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725011127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":46,"alternative-id":["S0165032725011127"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.119670","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Depression and suicide\/self-injury signals for weight loss medications: A disproportionality analysis of semaglutide, liraglutide, and tirzepatide in FAERS database","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.119670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119670"}}